Semaglutide works by activating the GLP-1 receptor to reduce appetite, increase fullness, and improve blood sugar regulation
Preserves the pulsatile pattern more faithfully, which some clinicians prefer for its more physiologic GH release profile
In 2023, the market was valued at approximately US $3.6 billion, and it is projected to reach $6.2 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 8% during the forecast period (20242030) [8]
A consultation does not guarantee semaglutide, tirzepatide, or any prescription
Researcher-led Protocols tested and refined by fellow researchers, not just sold
We offer GLP-1 Daily Support supplement, a supplement designed to help bridge nutritional gaps that can occur when your appetite is significantly reduced